Discovery of type II (covalent) inactivation of S-adenosyl-L-homocysteine hydrolase involving its "hydrolytic activity": synthesis and evaluation of dihalohomovinyl nucleoside analogues derived from adenosine

J Med Chem. 1998 Jul 30;41(16):3078-83. doi: 10.1021/jm9801410.

Abstract

Treatment of the 5'-carboxaldehyde derived by Moffatt oxidation of 6-N-benzoyl-2',3'-O-isopropylideneadenosine (1) with the "(bromofluoromethylene)triphenylphosphorane" reagent and deprotection gave 9-(6-bromo-5, 6-dideoxy-6-fluoro-beta-d-ribo-hex-5-enofuranosyl)adenine (4). Parallel treatment with a "dibromomethylene Wittig reagent" and deprotection gave 9-(6,6-dibromo-5, 6-dideoxy-beta-d-ribo-hex-5-enofuranosyl)adenine (7), which also was prepared by successive bromination and dehydrobromination of the 6'-bromohomovinyl nucleoside 8. Bromination-dehydrobromination of the 5'-bromohomovinyl analogue 11 and deprotection gave (E)-9-(5, 6-dibromo-5,6-dideoxy-beta-d-ribo-hex-5-enofuranosyl)adenine (15). Compounds 4, 7, and 15 were designed as putative substrates of the "hydrolytic activity" of S-adenosyl-l-homocysteine (AdoHcy) hydrolase. Enzyme-mediated addition of water across the 5,6-double bond could generate electrophilic acyl halide or alpha-halo ketone species that could undergo nucleophilic attack by proximal groups on the enzyme. Such type II (covalent) mechanism-based inactivation is supported by protein labeling with 8-[3H]-4 and concomitant release of bromide and fluoride ions. Incubation of AdoHcy hydrolase with 7 or 15 resulted in irreversible inactivation and release of bromide ion. In contrast with type I mechanism-based inactivation, reduction of enzyme-bound NAD+ to NADH was not observed. Compounds 4, 7, and 15 were not inhibitory to a variety of viruses in cell culture, and weak cytotoxicity was observed only for CEM cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosylhomocysteinase
  • Antiviral Agents / chemical synthesis
  • Antiviral Agents / pharmacology
  • Cell Line, Transformed
  • Dideoxyadenosine / analogs & derivatives*
  • Dideoxyadenosine / chemical synthesis
  • Dideoxyadenosine / pharmacology
  • Drug Design
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hydrolases / antagonists & inhibitors*
  • Hydrolysis
  • Microbial Sensitivity Tests
  • Placenta / enzymology
  • Recombinant Proteins / antagonists & inhibitors

Substances

  • 9-(5,6-dibromo-5,6-dideoxyhex-5-enofuranosyl)adenine
  • 9-(6,6-dibromo-5,6-dideoxyhex-5-enofuranosyl)adenine
  • 9-(6-bromo-5,6-dideoxy-6-fluorohex-5-enofuranosyl)adenine
  • Antiviral Agents
  • Enzyme Inhibitors
  • Recombinant Proteins
  • Dideoxyadenosine
  • Hydrolases
  • Adenosylhomocysteinase